Biovest International, Inc. (OTCBB:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), today announced that its Chairman and CEO, Dr. Steven Arikian, is scheduled to be interviewed on the “3 Minute Press Show,” an internet financial news program hosted by Tracee Tolentino and featured on Wall Street TV. The broadcast will air on Friday, April 25, 2008 and can be accessed at: http://tv.wallst.net
Additionally, Biovest announced that Dr. Arikian is scheduled to present at the Big Dog IV Small Cap Conference to be hosted at the Wynn Hotel in Las Vegas on Thursday, May 1, 2008 at 9:00 a.m.
Dr. Arikian commented, “Based on our recent news, it is not surprising that we are being asked to participate in media interviews and present at key investor events. I believe it is fair to say that BiovaxID is on track to potentially become the first ever cancer vaccine approved in the U.S. and/or Europe, initially targeting the treatment of non-Hodgkin's lymphoma (NHL), an insidious and often fatal cancer. The independent Data Monitoring Committee (DMC) just last week recommended stopping our Phase 3 clinical trial early and unblinding the results. The DMC has offered to meet with the FDA to assist in presenting the data and discussing accelerated and/or conditional approval. We are in the process of unblinding the results at this time. In addition to NHL, we believe the vaccine is capable of treating other forms of B-cell malignancy, covering many kinds of cancers.”
If qualified investors are interested in meeting with Dr. Arikian at the Big Dog IV Small Cap Conference in Las Vegas, please contact Douglas Calder at 813-864-2558 or dwcalder@biovest.com.
About BiovaxID®
BiovaxID is a personalized, patient-specific therapeutic vaccine designed to stimulate the patient's own immune system to recognize and destroy cancerous B-cells that may remain in the body or may arise after the patient has been treated with chemotherapy. Unlike many other approaches to treating non-Hodgkin’s lymphoma, BiovaxID is designed to kill only cancerous B-cells, with the initial indication of follicular Non-Hodgkin's lymphoma. Additionally, we anticipate that BiovaxID could potentially be used to treat other types of B-cell cancers, such as Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma.
About Biovest International, Inc.
Biovest International, Inc. (OTCBB:BVTI) is a pioneer in the development of advanced individualized immunotherapies for life-threatening cancers of the blood system. Biovest is a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., (NASDAQ:ABPI) with its remaining shares publicly traded. Biovest has a foundation in the manufacture of biologics for research and clinical trials. In addition, Biovest develops, manufactures and markets patented cell culture systems, including the innovative AutovaxID™, which is being marketed as an automated vaccine manufacturing instrument and for production of cell-based materials and therapeutics. Biovest is currently conducting a pivotal Phase 3 clinical trial for BiovaxID®, which is a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkin's lymphoma. BiovaxID has been granted Fast Track status by the FDA and Orphan Drug status by the EMEA.
For further information, please visit: http://www.biovest.com
Forward-Looking Statements: Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, statements about Revimmune™, BiovaxID®, AutovaxID™, and any other statements relating to products, product candidates, product development programs, the FDA or clinical study process including the commencement, process, or completion of clinical trials or the regulatory process. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, expectations and intentions, and other statements identified by words such as "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," or similar expressions.Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Biovest to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement, and Biovest undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. The product names used in this statement are for identification purposes only. All trademarks and registered trademarks are the property of their respective owners.
Contacts:
Corporate
Contacts:
Douglas Calder, Director of Investor Relations
&
Public Relations, 813-864-2554, ext.258
dwcalder@biovest.com
or
Susan
Bonitz, Ph.D., Director, Program Coordination
813-864-2554, ext.277
sbonitz@accentia.net
